Top

European Journal of Medical Research

Published in:

Open Access 01-12-2023 | Polyneuropathy | Research

Analysis of clinical features and risk factors of peripheral neuropathy in patients with primary Sjögren's syndrome

Authors: Zhihong Wu, Dong Wang, Lirong Chen, Kaipu Xianyu, Huiqing Yang

Published in: European Journal of Medical Research | Issue 1/2023

Abstract

Objective

To observe the clinical features and efficacy of immunosuppressive therapy in patients with primary Sjögren's syndrome (PSS) combined with peripheral neuropathy (PN) syndrome and to explore the risk factors for PN in patients with PSS.

Methods

Sixty consecutive patients with PSS admitted to the Department of Rheumatology and Immunology, Wuhan No. 1 Hospital, from January 2014 to June 2020 were analysed retrospectively. Patients were divided into a PN group (N = 15) and a non-PN group (N = 45). The clinical characteristics of the two groups were compared, and the independent risk factors for PN combined with PSS were analysed by multivariate logistic regression. The patients with PSS combined with PN were followed up to observe the effect of immunosuppressive therapy.

Results

The patients with PN had a longer course of disease than those without PN (z = − 3.225, P = 0.001), and the incidence of Raynaud's phenomenon, anti-SSB antibody, rheumatoid factor and hyperglobulinaemia was higher (all P < 0.05) in patients with PN than in those without PN. Multivariate logistic regression analysis showed that hyperglobulinaemia, RF and anti-SSB antibodies were independent risk factors for PN with PSS (P < 0.05). Fourteen patients with PSS-PN were treated with immunosuppressants. The clinical symptoms of 10 patients were relieved, and mRS scores of 10 patients were decreased.

Conclusion

PN is a common complication in PSS patients. Patients with PSS combined with PN have a longer course of disease and a significantly higher percentage of Raynaud's phenomenon, positive anti-SSB antibody, positive RF and hyperglobulinaemia. Immunosuppressive therapy was effective for partial remission of PN with PSS.

Qin B, Wang J, Yang Z, Yang M, Ma N, Huang F, et al. Epidemiology of primary Sjogren’s syndrome: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74(11):1983–9.CrossRef

Pavlakis PP, Alexopoulos H, Kosmidis ML, Stamboulis E, Routsias JG, Tzartos SJ, et al. Peripheral neuropathies in Sjogren syndrome: a new reappraisal. J Neurol Neurosurg Psychiatry. 2011;82(7):798–802.CrossRef

Lafitte C, Amoura Z, Cacoub P, Pradat-Diehl P, Picq C, Salachas F, et al. Neurological complications of primary Sjogren’s syndrome. J Neurol. 2001;248(7):577–84.CrossRef

Mori K, Iijima M, Koike H, Hattori N, Tanaka F, Watanabe H, et al. The wide spectrum of clinical manifestations in Sjogren’s syndrome-associated neuropathy. Brain. 2005;128(Pt 11):2518–34.CrossRef

Sopacua M, Hoeijmakers JGJ, Merkies ISJ, Lauria G, Waxman SG, Faber CG. Small-fiber neuropathy: expanding the clinical pain universe. J Peripher Nerv Syst. 2019;24(1):19–33.CrossRef

Vitali C. Classification criteria for Sjogren’s syndrome. Ann Rheum Dis. 2003;62(1):94–5 (author reply 5).CrossRef

Shiboski SC, Shiboski CH, Criswell L, Baer A, Challacombe S, Lanfranchi H, et al. American College of Rheumatology classification criteria for Sjogren’s syndrome: a data-driven, expert consensus approach in the Sjogren’s International Collaborative Clinical Alliance cohort. Arthritis Care Res. 2012;64(4):475–87.CrossRef

Dillingham T, Chen S, Andary M, Buschbacher R, Del Toro D, Smith B, et al. Establishing high-quality reference values for nerve conduction studies: a report from the normative data task force of the American Association of Neuromuscular & Electrodiagnostic Medicine. Muscle Nerve. 2016;54(3):366–70.CrossRef

Tankisi H, Pugdahl K, Fuglsang-Frederiksen A, Johnsen B, de Carvalho M, Fawcett PR, et al. Pathophysiology inferred from electrodiagnostic nerve tests and classification of polyneuropathies. Suggested guidelines. Clin Neurophysiol. 2005;116(7):1571–80.CrossRef

10.

Seror R, Ravaud P, Bowman SJ, Baron G, Tzioufas A, Theander E, et al. EULAR Sjogren’s syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren’s syndrome. Ann Rheum Dis. 2010;69(6):1103–9.CrossRef

11.

Vitali C. Measurement of disease activity and damage in Sjogren’s syndrome. Rheum Dis Clin North Am. 2008;34(4):963–71.CrossRef

12.

Jaskolska M, Chylinska M, Masiak A, Nowicka-Sauer K, Sieminski M, Zietkiewicz M, et al. Peripheral neuropathy and health-related quality of life in patients with primary Sjogren’s syndrome: a preliminary report. Rheumatol Int. 2020;40(8):1267–74.CrossRef

13.

Jaskolska M, Chylinska M, Masiak A, Sieminski M, Zietkiewicz M, Czuszynska Z, et al. Neuro-Sjogren: uncommon or underestimated problem? Brain Behav. 2020;10(8): e01665.CrossRef

14.

Gemignani F, Marbini A, Pavesi G, Di Vittorio S, Manganelli P, Cenacchi G, Mancia D. Peripheral neuropathy associated with primary. J Neurol Neurosurg Psychiatry. 1994;57(8):983–6.CrossRef

15.

Liampas A, Parperis K, Erotocritou MF, Nteveros A, Papadopoulou M, Moschovos C, et al. Primary Sjogren syndrome-related peripheral neuropathy: a systematic review and meta-analysis. Eur J Neurol. 2023;30(1):255–65.CrossRef

16.

Font J, Ramos-Casals M, de la Red G, Pou A, Casanova A, Garcia-Carrasco M, et al. Pure sensory neuropathy in primary Sjogren’s syndrome. Long term prospective follow up and review of the literature. J Rheumatol. 2003;30(7):1552–7.

17.

Tani J, Liao HT, Hsu HC, Chen LF, Chang TS, Shin-Yi Lin C, et al. Immune-mediated axonal dysfunction in seropositive and seronegative primary Sjogren’s syndrome. Ann Clin Transl Neurol. 2020;7(5):819–28.CrossRef

18.

Sene D, Jallouli M, Lefaucheur JP, Saadoun D, Costedoat-Chalumeau N, Maisonobe T, et al. Peripheral neuropathies associated with primary Sjogren syndrome: immunologic profiles of nonataxic sensory neuropathy and sensorimotor neuropathy. Medicine. 2011;90(2):133–8.CrossRef

19.

Sene D, Cacoub P, Authier FJ, Haroche J, Creange A, Saadoun D, et al. Sjogren syndrome-associated small fiber neuropathy: characterization from a prospective series of 40 cases. Medicine. 2013;92(5):e10–8.CrossRef

20.

Hsu CW, Su YJ, Chang WN, Tsai NW, Chiu WC, Cheng BC, et al. The association between serological biomarkers and primary Sjogren’s syndrome associated with peripheral polyneuropathy. Biomed Res Int. 2014;2014: 902492.CrossRef

21.

Jamilloux Y, Magy L, Hurtevent JF, Gondran G, de Seze J, Launay D, et al. Immunological profiles determine neurological involvement in Sjogren’s syndrome. Eur J Intern Med. 2014;25(2):177–81.CrossRef

22.

Ye W, Chen S, Huang X, Qin W, Zhang T, Zhu X, et al. Clinical features and risk factors of neurological involvement in Sjogren’s syndrome. BMC Neurosci. 2018;19(1):26.CrossRef

23.

Cafaro G, Perricone C, Carubbi F, Baldini C, Quartuccio L, Priori R, et al. Peripheral nervous system involvement in Sjogren’s syndrome: analysis of a cohort from the Italian research group on Sjogren’s syndrome. Front Immunol. 2021;12: 615656.CrossRef

24.

Ramos-Casals M, Brito-Zeron P, Bombardieri S, Bootsma H, De Vita S, Dorner T, et al. EULAR recommendations for the management of Sjogren’s syndrome with topical and systemic therapies. Ann Rheum Dis. 2020;79(1):3–18.CrossRef

25.

Pindi Sala T, Villedieu M, Damian L, Crave JC, Pautot V, Stojanovich L, et al. Long-term efficacy of immunoglobulins in small fiber neuropathy related to Sjogren’s syndrome. J Neurol. 2020;267(12):3499–507.CrossRef

26.

Mekinian A, Ravaud P, Hatron PY, Larroche C, Leone J, Gombert B, et al. Efficacy of rituximab in primary Sjogren’s syndrome with peripheral nervous system involvement: results from the AIR registry. Ann Rheum Dis. 2012;71(1):84–7.CrossRef

27.

Hirsch S, Skripuletz T, Seeliger T, Witte T, Thiele T. Selenium deficiency is associated with polyneuropathy in primary Sjogren’s syndrome. Clin Nutr ESPEN. 2022;50:212–7.CrossRef

Title: Analysis of clinical features and risk factors of peripheral neuropathy in patients with primary Sjögren's syndrome
Authors: Zhihong Wu
Dong Wang
Lirong Chen
Kaipu Xianyu
Huiqing Yang
Publication date: 01-12-2023
Publisher: BioMed Central
Keyword: Polyneuropathy
Published in: European Journal of Medical Research / Issue 1/2023
Electronic ISSN: 2047-783X
DOI: https://doi.org/10.1186/s40001-023-01013-w

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Analysis of clinical features and risk factors of peripheral neuropathy in patients with primary Sjögren's syndrome

Abstract

Objective

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2023

Hexarelin alleviates apoptosis on ischemic acute kidney injury via MDM2/p53 pathway

Education on medically unexplained symptoms: a systematic review with a focus on cultural diversity and migrants

Lifestyle factors, metabolic factors and socioeconomic status for pelvic organ prolapse: a Mendelian randomization study

The emerging roles of N6-methyladenosine RNA modifications in thyroid cancer

Propensity matched analysis examining the effect of passive reversal of direct oral anticoagulants on blood loss and the need for transfusions among traumatic geriatric hip fractures

Prognosis of coronary heart disease after percutaneous coronary intervention: a bibliometric analysis over the period 2004–2022